CAR-T cell therapy company Poseida Therapeutics is seeking to raise $115m in an initial public offering (IPO), according to papers filed with securities regulators. The company, which has been developing a treatment for multiple myeloma, said it plans to list its shares on the Nasdaq exchange under ticker symbol PRXT. The company wants to use any IPO proceedings to further fund clinical development and research of its CAR-T treatment for relapsed/refractory multiple myeloma. It may also set up a pilot manufacturing unit, with an estimated cost of up to $15m, the filing showed.
CAR-T cell therapy company Poseida Therapeutics is seeking to raise $115m in an initial public offering (IPO), according to papers filed with securities regulators. Poseida, which is testing CAR-T cell therapies for blood-borne and solid tumour cancers, has filed for a Nasdaq listing under the symbol PSTX. The company wants to use any IPO proceedings to further fund clinical development and research of its CAR-T treatment for relapsed/refractory multiple myeloma. It may also set up a pilot manufacturing unit, with an estimated cost of up to $15m, the filing showed.